Skip to main content

An Overview on Brazilian Patent Prosecution

Brazilian patent prosecution refers to the process of applying for and obtaining a patent in Brazil. It involves various steps and interactions with the Brazilian Patent and Trademark Office (Instituto Nacional da Propriedade Industrial or INPI) to seek protection for an invention and have it granted as a patent.

The patent prosecution process in Brazil typically includes the following steps:

1. **Patent Application Filing**: The first step is to file a patent application with the INPI. The application must include a detailed description of the invention, claims defining the scope of protection sought, and any necessary drawings or diagrams.

2. **Formal Examination**: The INPI conducts a formal examination to check if the application meets the necessary formal requirements, such as proper documentation, payment of fees, and correct filing procedures.

3. **Publication**:  After passing the formal examination, the patent application is published in the Brazilian Official Gazette. This publication allows interested parties to review the application and file pre-grant oppositions if they believe the invention should not be patented.

4. **Substantive Examination**: The INPI conducts a substantive examination to assess the patent application's novelty, inventive step, and industrial applicability. This examination ensures that the invention meets the patentability criteria set out in Brazilian law.

5. **Office Actions**: If the examiner finds any issues or deficiencies in the application, an office action is issued, detailing the objections or requirements that must be addressed before the patent can be granted. The applicant has the opportunity to respond to these office actions to overcome the objections.

6. **Grant or Rejection**: If the patent application meets all the requirements and the INPI is satisfied with the responses to any office actions, the patent will be granted. However, if the INPI is not convinced of the patentability of the invention or the applicant does not overcome the objections, the patent application may be rejected.

7. **Maintenance and Renewal**: Once the patent is granted, the owner is responsible for maintaining it by paying the required maintenance fees. These fees are typically due annually, and failure to pay them could result in the patent's expiration.

It's worth noting that the patent prosecution process can be time-consuming, and the timeline for obtaining a patent in Brazil can vary depending on the complexity of the invention and the workload of the INPI. It is essential to have a thorough understanding of Brazilian patent law and procedural requirements or seek the assistance of a qualified patent attorney to navigate the process effectively.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em

Novo Nordisk settles with 2 Florida venders of compounded (Semaglutide)Ozempic:

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing

Hypertension-An Overview

INTRODUCTION: Systemic arterial hypertension is one of the strongest known modifiable risk factors for ischaemic heart disease, stroke, renal failure and heart failure. It remains poorly treated. As an asymptomatic disorder, people are understandably reluctant to accept adverse drug effects in addition to the inconvenience of long-term treatment. In this regard, modern drugs represent an enormous improvement. PATHOPHYSIOLOGY AND SITES OF DRUG ACTION Hypertension is occasionally secondary to some distinct disease. However, most patients with persistent arterial hypertension have essential hypertension. Arterial blood pressure is determined by cardiac output, peripheral vascular resistance and large artery compliance. Peripheral vascular resistance is determined by the diameter of resistance vessels (small muscular arteries and arterioles) in the various tissues. One or more of a ‘mosaic’ of interconnected predisposing factors (including positive family history, obesity and phys